Allarity Therapeutics Inc
ALLR
NASDAQ
Biotechnology
$1.37
USD
+0.01 (+0.74%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $21.64M
Volume 45.5K
Revenue
$345,000
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-11.25M
TTM
+51.9%
YoY
Operating Cash Flow
$-16.63M
TTM
+10.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 |
Selling, General & Administrative | 1.6 | 1.8 | 1.3 | 1.6 | 1.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.0 | 4.1 | 2.5 | 3.2 | 2.7 |
Operating Income | -3.0 | -4.1 | -2.5 | -2.9 | -2.7 |
EBITDA | -3.0 | -4.1 | -2.6 | -2.9 | -2.7 |
Other Income / Expense | 0.1 | 1.6 | -0.4 | -0.6 | 0.0 |
Total Other Income / Expense | 0.3 | 1.8 | -0.3 | -0.5 | -0.1 |
Income Before Income Taxes | -2.7 | -2.3 | -2.8 | -3.4 | -2.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.7 | -2.3 | -2.8 | -3.4 | -2.8 |
Consolidated Net Income / Loss | -2.7 | -2.3 | -2.8 | -3.4 | -2.8 |
Net Income Attributable to Common Shareholders | -2.7 | -2.3 | -2.8 | -3.4 | -2.8 |
Basic EPS | -$0.25 | -$0.15 | -$0.19 | -$0.21 | -$0.17 |
Diluted EPS | -$0.25 | -$0.15 | -$0.19 | -$0.21 | -$0.17 |
Basic Shares Outstanding | 11.1M | 15.5M | 14.7M | 16.1M | 16.0M |
Diluted Shares Outstanding | 11.1M | 15.5M | 14.7M | 16.1M | 16.0M |